Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TITAN-RCC: Tailored Immunotherapy with Nivolumab in Advanced RCC
NCT02917772Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Oct 2016
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in clear cell renal cell carcinoma (ccRCC), sponsored by AIO-Studien. Primary endpoint: Objective Response Rate. Started Oct 2016; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT02917772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02917772.